Survival, functional outcomes and safety in patients with thymidine kinase 2 deficiency (TK2d) and an age of TK2d symptom onset ≤12 years who received pyrimidine nucleos(t)ide therapy

Important Information Related to Your Request:

Doxecitine and Doxribtimine is an investigational product in clinical development. The safety and efficacy have not been established and it is not approved by the Food and Drug Administration, or by any health authority worldwide.

The material below is provided in response to your specific search for information on UCBCOMPASS®. It is not intended to draw any conclusion regarding the efficacy and safety of Doxecitine and Doxribtimine for any indication, dosage, or other claim.